WVE
WAVE Life Sciences Ltd
$
8.105
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
8.110
Open
8.040
VWAP
7.95
Vol
2.01M
Mkt Cap
1.29B
Low
7.800
Amount
15.94M
EV/EBITDA(TTM)
--
Total Shares
122.48M
EV
1.09B
EV/OCF(TTM)
--
P/S(TTM)
13.39
Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
11.37M
+23.92%
-0.310
+6.78%
18.13M
-78.35%
-0.232
-185.88%
12.22M
-259.15%
-0.285
-39.34%
Estimates Revision
The market is revising Downward the revenue expectations for Wave Life Sciences Ltd. (WVE) for FY2025, with the revenue forecasts being adjusted by -21.61% over the past three months. During the same period, the stock price has changed by 22.80%.
Revenue Estimates for FY2025
Revise Downward
-21.61%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+13.52%
In Past 3 Month
Stock Price
Go Up
+22.80%
In Past 3 Month
13 Analyst Rating
125.17% Upside
Wall Street analysts forecast WVE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WVE is 18.25 USD with a low forecast of 9.00 USD and a high forecast of 24.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
1 Hold
0 Sell
Strong Buy
125.17% Upside
Current: 8.105
Low
9.00
Averages
18.25
High
24.00
125.17% Upside
Current: 8.105
Low
9.00
Averages
18.25
High
24.00
Canaccord
initiated
$19
2025-08-04
Reason
Canaccord
Price Target
$19
2025-08-04
initiated
Reason
Canaccord initiated coverage of Wave Life Sciences with a Buy rating and $19 price target.
Canaccord
initiated
$19
2025-08-04
Reason
Canaccord
Price Target
$19
2025-08-04
initiated
Reason
Canaccord initiated coverage of Wave Life Sciences with a Buy rating and $19 price target. The firm believes now is the time to buy Wave Life shares. The company's "robust" pipeline includes potential milestone and future royalty payments associated with WVE-006 for alpha-1 antitrypsin deficiency, a large obesity opportunity with WVE-007, a potential first commercial approval of WVE-N531 for Exon 53 in the next year, and WVE-003 for Huntington disease, the analyst tells investors in a research note.
Oppenheimer
Outperform
initiated
$24
2025-07-28
Reason
Oppenheimer
Price Target
$24
2025-07-28
initiated
Outperform
Reason
Oppenheimer initiated coverage of Wave Life Sciences with an Outperform rating and $24 price target. The firm views Wave as a leading innovator in advancing RNA medicine with four clinical-stage programs. The analyst is optimistic about WVE-006 and WVE-007, saying they represent first-in-class programs. Opco sees catalysts from both programs in the second half of 2025.
Citi
initiated
$16
2025-07-16
Reason
Citi
Price Target
$16
2025-07-16
initiated
Reason
Citi initiated coverage of Wave Life Sciences with a Buy rating and $16 price target. Wave is a clinical-staged biotech company developing a pipeline of RNA medicines for rare and common diseases, the analyst tells investors in a research note. The firm sees several near-term data catalysts for Wave with potential for upside.
Raymond James
Outperform
initiated
$14
2025-06-10
Reason
Raymond James
Price Target
$14
2025-06-10
initiated
Outperform
Reason
Raymond James assumed coverage of Wave Life Sciences with an Outperform rating and $14 price target as part of a broader research note on selection Biotech names. Risk/reward skews favorably across the sector, though while companies with high PoS - probability of success - lead assets allow for higher conviction, highly attractive skews on less de-risked assets may deliver the most outsized returns, the analyst tells investors in a research note. For the company, the firm is positive on the risk-reward opportunity ahead of second-half catalysts for its two most important clinical-stage programs - WVE-007 in obesity, which features a novel mechanism with differentiating qualities, and WVE-006 in AATD, with second half updates that will include larger cohorts at repeat and higher doses, Raymond James added.
HC Wainwright & Co.
Andrew Fein
Strong Buy
Reiterates
$22
2025-03-26
Reason
HC Wainwright & Co.
Andrew Fein
Price Target
$22
2025-03-26
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for WAVE Life Sciences Ltd (WVE.O) is -6.75, compared to its 5-year average forward P/E of -4.89. For a more detailed relative valuation and DCF analysis to assess WAVE Life Sciences Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.89
Current PE
-6.75
Overvalued PE
-1.77
Undervalued PE
-8.01
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-2.17
Current EV/EBITDA
-5.78
Overvalued EV/EBITDA
1.04
Undervalued EV/EBITDA
-5.38
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Overvalued
5Y Average PS
12.51
Current PS
26.50
Overvalued PS
20.74
Undervalued PS
4.28
Financials
Annual
Quarterly
FY2025Q2
YoY :
-55.82%
8.70M
Total Revenue
FY2025Q2
YoY :
+50.75%
-52.76M
Operating Profit
FY2025Q2
YoY :
+53.29%
-50.47M
Net Income after Tax
FY2025Q2
YoY :
+24.00%
-0.31
EPS - Diluted
FY2025Q2
YoY :
+68.31%
-46.32M
Free Cash Flow
FY2025Q2
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q2
YoY :
+81.59%
-213.01
FCF Margin - %
FY2025Q2
YoY :
+247.01%
-580.17
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
261.0K
USD
3
3-6
Months
1.7M
USD
2
6-9
Months
0.0
USD
0
0-12
Months
6.4M
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
16.5M
USD
Months
0-12
1
22.3M
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
261.0K
USD
3
3-6
Months
1.7M
USD
2
6-9
Months
0.0
USD
0
0-12
Months
6.4M
USD
6
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
1
16.5M
USD
Months
0-12
1
22.3M
USD
Months
WVE News & Events
Events Timeline
2025-07-30 (ET)
2025-07-30
07:33:56
Wave Life Sciences sees cash runway into 2027
2025-07-30
07:33:26
Wave Life Sciences reports Q2 EPS (31c), consensus (28c)
2025-05-28 (ET)
2025-05-28
08:11:46
Wave Life Sciences announces appointment of Wright as CMO
Sign Up For More Events
Sign Up For More Events
News
7.5
08-06PRnewswireXtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration
4.0
08-04BenzingaThis AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
4.0
08-04BenzingaCanaccord Genuity Initiates Coverage On WAVE Life Sciences with Buy Rating, Announces Price Target of $19
Sign Up For More News
People Also Watch
PCT
Purecycle Technologies Inc
12.790
USD
+3.56%
NBHC
National Bank Holdings Corp
36.530
USD
-0.03%
GNL
Global Net Lease Inc
7.410
USD
-3.52%
NN
NextNav Inc
14.440
USD
+5.02%
MNKD
MannKind Corp
3.420
USD
-2.84%
VVX
V2X Inc
52.930
USD
+4.23%
DBD
Diebold Nixdorf Inc
59.690
USD
-0.50%
CLBK
Columbia Financial Inc
14.300
USD
-0.21%
AMBP
Ardagh Metal Packaging SA
3.860
USD
+2.39%
FAQ
What is WAVE Life Sciences Ltd (WVE) stock price today?
The current price of WVE is 8.105 USD — it has increased 0.19 % in the last trading day.
What is WAVE Life Sciences Ltd (WVE)'s business?
What is the price predicton of WVE Stock?
What is WAVE Life Sciences Ltd (WVE)'s revenue for the last quarter?
What is WAVE Life Sciences Ltd (WVE)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for WAVE Life Sciences Ltd (WVE)'s fundamentals?
How many employees does WAVE Life Sciences Ltd (WVE). have?